---
title: "Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275767804.md"
datetime: "2026-02-12T14:02:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275767804.md)
  - [en](https://longbridge.com/en/news/275767804.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275767804.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275767804.md) | [English](https://longbridge.com/en/news/275767804.md)


# Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics

Feb 12 (Reuters) - Aprea Therapeutics Inc (APRE.O) : \* APREA THERAPEUTICS STRENGTHENS GLOBAL PATENT PORTFOLIO IN DNA DAMAGE RESPONSE (DDR) CANCER THERAPEUTICS, PAVING WAY FOR PIPELINE GROWTH \* APREA THERAPEUTICS INC - GRANTED NEW PATENTS IN AUSTRALIA AND JAPAN \* APREA THERAPEUTICS INC - CORE PATENT FAMILIES EXPECTED TO PROVIDE EXCLUSIVITY INTO 2045 \* APREA THERAPEUTICS INC - EXISTING ISSUED PATENTS EXPECTED TO REMAIN IN FORCE THROUGH 2035-2037 Source text: Further company coverage: (APRE.O)

### 相關股票

- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [Aprea Therapeutics (APRE.US)](https://longbridge.com/zh-HK/quote/APRE.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)

## 相關資訊與研究

- [Aprea Therapeutics Q4 net loss narrows as R&D costs fall](https://longbridge.com/zh-HK/news/279262230.md)
- [Trevi Therapeutics Maps Phase III Path and Runway](https://longbridge.com/zh-HK/news/279703997.md)
- [Halozyme Therapeutics Touts $1.8B Revenue Outlook, ENHANZE Royalties and New Hypercon Deals at Conference](https://longbridge.com/zh-HK/news/279535511.md)
- [Aprea Therapeutics 10-K: $0.286M Grant Revenue, Loss per Share $(1.93)](https://longbridge.com/zh-HK/news/279266764.md)
- [Zydus Lifesciences Limited Announces Desidustat Tablets Approval for Renal Anaemia in China](https://longbridge.com/zh-HK/news/279128988.md)